---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-023258"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2022-08-17T23:59:59+00:00"
generated_at: "2026-06-23T23:06:00.720305+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bioxytran raises $600K in private placement for Covid-19, lung fibrosis clinical trials

## Summary
- Issued 1.4M shares at $0.4286/share to an accredited investor for gross proceeds of $600,000.
- Net proceeds of $576,000 after 4% placement agent fee paid to WallachBeth Capital.
- Proceeds intended for down-payment on human trials of ProLectin-M (oral) for Covid-19 and ProLectin-I (IV) for lung fibrosis.
- Shares offered on best-efforts basis; no minimum offering amount; funds available immediately upon acceptance.

## SEC filing metadata
- accession: 0001493152-22-023258
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2022-08-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315222023258/0001493152-22-023258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315222023258/form-8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-023258
- JSON: https://secwatch.observer/filing/0001493152-22-023258.json
- Plain text: https://secwatch.observer/filing/0001493152-22-023258.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.